{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:48:55Z","timestamp":1793972935944,"version":"4.8.0"},"reference-count":287,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":372,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["20220484207"],"award-info":[{"award-number":["20220484207"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA1201000"],"award-info":[{"award-number":["2021YFA1201000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2302400"],"award-info":[{"award-number":["2021YFC2302400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFE0106900"],"award-info":[{"award-number":["2021YFE0106900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2022CX01013"],"award-info":[{"award-number":["2022CX01013"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ymthe.2024.01.005","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T21:21:35Z","timestamp":1704835295000},"page":"284-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":242,"title":["The landscape of nanoparticle-based siRNA delivery and therapeutic development"],"prefix":"10.1016","volume":"32","author":[{"given":"Muhammad","family":"Moazzam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abid","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3935-7245","authenticated-orcid":false,"given":"Yuanyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.01.005_bib1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.01.005_bib2","doi-asserted-by":"crossref","first-page":"9742","DOI":"10.1073\/pnas.171251798","article-title":"Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems","volume":"98","author":"Caplen","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.01.005_bib3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.01.005_bib4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.59566\/IJBS.2017.13048","article-title":"Molecular mechanisms and biological functions of siRNA","volume":"13","author":"Dana","year":"2017","journal-title":"Int. J. Biomed. Sci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11427-018-9438-y","article-title":"siRNA therapeutics: a clinical reality","volume":"63","author":"Saw","year":"2020","journal-title":"Sci. China. Life Sci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib6","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","article-title":"Patisiran: First global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2024.01.005_bib7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: First approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2024.01.005_bib8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","article-title":"Lumasiran: first approval","volume":"81","author":"Scott","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2024.01.005_bib9","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/ph13100294","article-title":"Overcoming barriers for sirna therapeutics: from bench to bedside","volume":"13","author":"Sajid","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ymthe.2024.01.005_bib10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking down barriers: advances in siRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2024.01.005_bib11","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1208\/s12248-010-9210-4","article-title":"Delivery of siRNA therapeutics: barriers and carriers","volume":"12","author":"Wang","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.ymthe.2024.01.005_bib12","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1242\/jcs.066399","article-title":"Breaking down the barriers: siRNA delivery and endosome escape","volume":"123","author":"Dominska","year":"2010","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib13","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3390\/molecules24040809","article-title":"The pharmaceutical industry in 2018. An analysis of FDA drug approvals from the perspective of molecules","volume":"24","author":"G de la Torre","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ymthe.2024.01.005_bib14","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3390\/molecules25030745","article-title":"The pharmaceutical industry in 2019. An analysis of FDA drug approvals from the perspective of molecules","volume":"25","author":"de la Torre","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ymthe.2024.01.005_bib15","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3390\/molecules26030627","article-title":"The pharmaceutical industry in 2020. An analysis of FDA drug approvals from the perspective of molecules","volume":"26","author":"Torre","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ymthe.2024.01.005_bib16","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/molecules27031075","article-title":"The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals from the Perspective of Molecules","volume":"27","author":"de la Torre","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ymthe.2024.01.005_bib17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1517\/17425247.2011.559223","article-title":"Recent advances of siRNA delivery by nanoparticles","volume":"8","author":"Yuan","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ymthe.2024.01.005_bib18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jconrel.2007.05.021","article-title":"Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery","volume":"121","author":"Gary","year":"2007","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.ymthe.2024.01.005_bib19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2217\/nnm.13.192","article-title":"Lipid-based nanoparticles in the systemic delivery of siRNA","volume":"9","author":"Lin","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ymthe.2024.01.005_bib20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.biomaterials.2011.09.061","article-title":"Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors","volume":"33","author":"Zhou","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2024.01.005_bib21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1039\/C5BM00277J","article-title":"Utilising inorganic nanocarriers for gene delivery","volume":"4","author":"Loh","year":"2016","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10565-009-9141-y","article-title":"Multifunctional nanocomplexes for gene transfer and gene therapy","volume":"26","author":"Hart","year":"2010","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib23","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2174\/138920010791110863","article-title":"Nanoparticle-Based Delivery System for Application of siRNA","volume":"11","author":"Wang","year":"2010","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ymthe.2024.01.005_bib24","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1517\/17425247.2016.1134486","article-title":"Progress and perspective of inorganic nanoparticle-based siRNA delivery systems","volume":"13","author":"Jiang","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ymthe.2024.01.005_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/ph6010085","article-title":"Nanoparticle-based delivery of RNAi therapeutics: progress and challenges","volume":"6","author":"Zhou","year":"2013","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ymthe.2024.01.005_bib26","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.addr.2009.04.004","article-title":"siRNA vs. shRNA: Similarities and differences","volume":"61","author":"Rao","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2024.01.005_bib27","first-page":"141","article-title":"Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown","volume":"629","author":"Moore","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tibs.2004.12.007","article-title":"siRNA and miRNA: an insight into RISCs","volume":"30","author":"Tang","year":"2005","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib29","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","article-title":"mRNA-based cancer therapeutics","volume":"23","author":"Liu","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2024.01.005_bib30","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","article-title":"The landscape of mRNA nanomedicine","volume":"28","author":"Huang","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.01.005_bib31","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41419-022-05075-2","article-title":"RNA-based therapeutics: an overview and prospectus","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2024.01.005_bib32","first-page":"2849","article-title":"The Nobel Prize in Physiology or Medicine for 2006 for the discovery of RNA interference","volume":"150","author":"Bernards","year":"2006","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"10.1016\/j.ymthe.2024.01.005_bib33","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","article-title":"Eteplirsen: First global approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2024.01.005_bib34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ymgme.2016.04.001","article-title":"The case for eteplirsen: Paving the way for precision medicine","volume":"118","author":"Miceli","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2024.01.005_bib35","first-page":"14","article-title":"Fomivirsen approved for CMV retinitis","volume":"4","author":"Roehr","year":"1998","journal-title":"J.\u00a0Int. Assoc. Physicians AIDS Care"},{"key":"10.1016\/j.ymthe.2024.01.005_bib36","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","article-title":"FDA-approved oligonucleotide therapies in 2017","volume":"25","author":"Stein","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.01.005_bib37","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","article-title":"Inotersen: First global approval","volume":"78","author":"Keam","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2024.01.005_bib38","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: First global approval","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2024.01.005_bib39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14656566.2018.1550071","article-title":"Mipomersen and its use in familial hypercholesterolemia","volume":"20","author":"Parham","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ymthe.2024.01.005_bib40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"Golodirsen: First Approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2024.01.005_bib41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000517686","article-title":"Antisense oligonucleotide therapy for neurodevelopmental disorders","volume":"43","author":"Hill","year":"2021","journal-title":"Dev. Neurosci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib42","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: First Approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2024.01.005_bib43","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/molecules27020536","article-title":"Small drugs, huge impact: The extraordinary impact of antisense oligonucleotides in research and drug development","volume":"27","author":"Quemener","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ymthe.2024.01.005_bib44","doi-asserted-by":"crossref","first-page":"198114","DOI":"10.1016\/j.virusres.2020.198114","article-title":"COVID-19 Vaccine: A comprehensive status report","volume":"288","author":"Kaur","year":"2020","journal-title":"Virus Res."},{"key":"10.1016\/j.ymthe.2024.01.005_bib45","doi-asserted-by":"crossref","first-page":"329","DOI":"10.15585\/mmwr.mm7009e4","article-title":"The advisory committee on immunization practices\u2019 interim recommendation for use of Janssen COVID-19 vaccine-United States, February 2021","volume":"70","author":"Oliver","year":"2021","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.ymthe.2024.01.005_bib46","first-page":"71","article-title":"Formulation and delivery technologies for mRNA vaccines","volume":"440","author":"Zeng","year":"2022","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib47","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1039\/D1CS00617G","article-title":"Emerging mRNA technologies: delivery strategies and biomedical applications","volume":"51","author":"Xiao","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ymthe.2024.01.005_bib48","doi-asserted-by":"crossref","first-page":"120586","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ymthe.2024.01.005_bib49","series-title":"Detection and Diagnostics of Plant Pathogens","first-page":"21","article-title":"siRNA deep sequencing and assembly: piecing together viral infections","author":"Kreuze","year":"2014"},{"key":"10.1016\/j.ymthe.2024.01.005_bib50","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA Versus miRNA as Therapeutics for Gene Silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2024.01.005_bib51","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3390\/biomedicines9040433","article-title":"The challenges and strategies of antisense oligonucleotide drug delivery","volume":"9","author":"Gagliardi","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymthe.2024.01.005_bib52","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.chembiol.2011.12.008","article-title":"RNA-based therapeutics: Current progress and future prospects","volume":"19","author":"Burnett","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib53","doi-asserted-by":"crossref","first-page":"107534","DOI":"10.1016\/j.biotechadv.2020.107534","article-title":"The challenge and prospect of mRNA therapeutics landscape","volume":"40","author":"Weng","year":"2020","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ymthe.2024.01.005_bib54","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/d41586-019-03068-4","article-title":"RNA therapies explained","volume":"574","author":"Deweerdt","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.01.005_bib55","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt1051","article-title":"Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy","volume":"23","author":"Kim","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib56","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd4685","article-title":"Clinical experiences with systemically administered siRNA-based therapeutics in cancer","volume":"14","author":"Zuckerman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2024.01.005_bib57","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1261\/rna.5103703","article-title":"siRNA function in RNAi: A chemical modification analysis","volume":"9","author":"Chiu","year":"2003","journal-title":"RNA"},{"key":"10.1016\/j.ymthe.2024.01.005_bib58","doi-asserted-by":"crossref","first-page":"2100108","DOI":"10.1002\/adtp.202100108","article-title":"Overcoming Barriers: Clinical Translation of siRNA Nanomedicines","volume":"4","author":"Tieu","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ymthe.2024.01.005_bib59","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nrc2966","article-title":"RNA interference in the clinic: challenges and future directions","volume":"11","author":"Pecot","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2024.01.005_bib60","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1021\/acs.accounts.2c00464","article-title":"Overcoming pharmaceutical bottlenecks for nucleic acid drug development","volume":"56","author":"Lu","year":"2023","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ymthe.2024.01.005_bib61","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.molmed.2022.08.003","article-title":"siRNA modification and delivery for drug development","volume":"28","author":"Zhang","year":"2022","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ymthe.2024.01.005_bib62","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jconrel.2013.10.003","article-title":"RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system","volume":"173","author":"Sakurai","year":"2014","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.ymthe.2024.01.005_bib63","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nbt1101","article-title":"Antibody mediated delivery of small interfering RNAs via cell-surface receptors","volume":"23","author":"Song","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib64","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1124\/jpet.119.256909","article-title":"Effectiveness of small interfering rna delivery via arginine-rich polyethylenimine-based polyplex in metastatic and doxorubicin-resistant breast cancer cells","volume":"370","author":"Lu","year":"2019","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ymthe.2024.01.005_bib65","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/mt.2012.185","article-title":"The possible \u201cproton sponge\u201d effect of polyethylenimine (PEI) does not include change in lysosomal pH","volume":"21","author":"Benjaminsen","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.01.005_bib66","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.biomaterials.2018.01.042","article-title":"Dual-responsive polyplexes with enhanced disassembly and endosomal escape for efficient delivery of siRNA","volume":"162","author":"Zhu","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2024.01.005_bib67","doi-asserted-by":"crossref","first-page":"1900018","DOI":"10.1002\/adfm.201900018","article-title":"Binary targeting of siRNA to hematologic cancer cells in\u00a0vivo using layer-by-layer nanoparticles","volume":"29","author":"Choi","year":"2019","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.ymthe.2024.01.005_bib68","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1016\/j.biomaterials.2013.03.010","article-title":"Synergistic gene and drug tumor therapy using a chimeric peptide","volume":"34","author":"Han","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2024.01.005_bib69","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/nano8050270","article-title":"Cationic liposomes carrying sirna: impact of lipid composition on physicochemical properties, cytotoxicity and endosomal escape","volume":"8","author":"Lechanteur","year":"2018","journal-title":"Nanomaterials"},{"key":"10.1016\/j.ymthe.2024.01.005_bib70","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.addr.2007.03.006","article-title":"RNA interference and innate immunity","volume":"59","author":"Sioud","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2024.01.005_bib71","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/nano7040077","article-title":"siRNA delivery strategies: a comprehensive review of recent developments","volume":"7","author":"Tatiparti","year":"2017","journal-title":"Nanomaterials"},{"key":"10.1016\/j.ymthe.2024.01.005_bib72","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1039\/D1CS01148K","article-title":"Minimally invasive nanomedicine: nanotechnology in photo-\/ultrasound-\/radiation-\/magnetism-mediated therapy and imaging","volume":"51","author":"Ouyang","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ymthe.2024.01.005_bib73","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/sj.cgt.7700145","article-title":"A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1","volume":"7","author":"Stuart","year":"2000","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2024.01.005_bib74","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/sj.gt.3301506","article-title":"On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids","volume":"8","author":"Hafez","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2024.01.005_bib75","doi-asserted-by":"crossref","first-page":"120033","DOI":"10.1016\/j.ijpharm.2020.120033","article-title":"Assembly strategy of liposome and polymer systems for siRNA delivery","volume":"592","author":"Song","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ymthe.2024.01.005_bib76","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1158\/1535-7163.MCT-16-0541","article-title":"Preclinical mammalian safety studies of EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA)","volume":"16","author":"Wagner","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2024.01.005_bib77","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3390\/pharmaceutics13040479","article-title":"Viscous core liposomes increase siRNA encapsulation and provides gene inhibition when slightly positively charged","volume":"13","author":"Ahmed","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2024.01.005_bib78","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41392-021-00859-y","article-title":"Ionizable liposomal siRNA therapeutics enables potent and persistent treatment of Hepatitis B","volume":"7","author":"Huang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2024.01.005_bib79","first-page":"1053","article-title":"Efficient hepatic delivery and protein expression enabled by optimized mRNA and ionizable lipid nanoparticle","volume":"5","author":"Yang","year":"2020","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.ymthe.2024.01.005_bib80","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1242\/jcs.00252","article-title":"The pairing of X and Y chromosomes during meiotic prophase in the marsupial species is maintained by a dense plate developed from their axial elements","volume":"116","author":"Page","year":"2003","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib81","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/gt.2009.76","article-title":"An immobilized nanoparticle-based platform for efficient gene knockdown of targeted cells in the circulation","volume":"16","author":"Huang","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2024.01.005_bib82","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2796.2009.02191.x","article-title":"Nanomedicine based approaches for the delivery of siRNA in cancer","volume":"267","author":"Ozpolat","year":"2010","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.ymthe.2024.01.005_bib83","doi-asserted-by":"crossref","first-page":"22639","DOI":"10.1074\/jbc.M110.125906","article-title":"Multifunctional Nanoparticles Delivering Small Interfering RNA and Doxorubicin Overcome Drug Resistance in Cancer","volume":"285","author":"Chen","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2024.01.005_bib84","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1208\/s12249-015-0394-x","article-title":"Physical-Chemical Characterization and Formulation Considerations for Solid Lipid Nanoparticles","volume":"17","author":"Chauhan","year":"2016","journal-title":"Aaps Pharmscitech"},{"key":"10.1016\/j.ymthe.2024.01.005_bib85","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejpb.2013.08.013","article-title":"Solid lipid nanoparticles (sln) and nanostructured lipid carriers (NLC) for pulmonary application: A review of the state of the art","volume":"86","author":"Weber","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ymthe.2024.01.005_bib86","first-page":"1407","article-title":"Review on nanoparticles used in cosmetics and dermal products","volume":"3","author":"Patwekar","year":"2014","journal-title":"World J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib87","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.addr.2020.07.022","article-title":"Recent advances in siRNA delivery mediated by lipid-based nanoparticles","volume":"154\u2013155","author":"Yonezawa","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2024.01.005_bib88","series-title":"Applications of Lipidic and Polymeric Nanoparticles for siRNA Delivery","author":"\u015eenel","year":"2019"},{"key":"10.1016\/j.ymthe.2024.01.005_bib89","doi-asserted-by":"crossref","first-page":"305","DOI":"10.15171\/apb.2015.043","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application","volume":"5","author":"Naseri","year":"2015","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.ymthe.2024.01.005_bib90","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejpb.2011.11.002","article-title":"Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA","volume":"80","author":"Yu","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ymthe.2024.01.005_bib91","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.biomaterials.2012.09.067","article-title":"Cationic solid lipid nanoparticles derived from apolipoprotein-free LDLs for target specific systemic treatment of liver fibrosis","volume":"34","author":"Kong","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2024.01.005_bib92","doi-asserted-by":"crossref","first-page":"9977","DOI":"10.1021\/nn203745n","article-title":"Sustained release of sirna from solid lipid nanoparticles","volume":"5","author":"Lobovkina","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.ymthe.2024.01.005_bib93","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1002\/jps.22147","article-title":"Biodegradable nanoparticles with sustained release of functional sirna in skin","volume":"99","author":"Jacobson","year":"2010","journal-title":"J.\u00a0Pharm. Sci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib94","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1021\/acs.molpharmaceut.9b00629","article-title":"Effect of the ratio of betamethasone to TNF-\u03b1 siRNA Coencapsulated in solid lipid nanoparticles on the acute Proinflammatory activity of the nanoparticles","volume":"16","author":"O\u2019Mary","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2024.01.005_bib95","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1023\/A:1016090420759","article-title":"Evidence for phospholipid bilayer formation in solid lipid nanoparticles formulated with phospholipid and triglyceride","volume":"13","author":"Heiati","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ymthe.2024.01.005_bib96","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1049\/iet-nbt.2017.0001","article-title":"Docetaxel-loaded solid lipid nanoparticles: a novel drug delivery system","volume":"11","author":"Sumera, Anwar","year":"2017","journal-title":"IET nanobiotechnol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib97","first-page":"27","article-title":"Nanostructured lipid carriers and their current application in targeted drug delivery","volume":"44","author":"Jaiswal","year":"2016","journal-title":"Artif. Cell Nanomed B"},{"key":"10.1016\/j.ymthe.2024.01.005_bib98","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jconrel.2013.04.018","article-title":"Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA","volume":"171","author":"Taratula","year":"2013","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.ymthe.2024.01.005_bib99","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s13346-020-00723-6","article-title":"Nanostructured lipid carrier co-delivering tacrolimus and TNF-\u03b1 siRNA as an innovate approach to psoriasis","volume":"10","author":"Viegas","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ymthe.2024.01.005_bib100","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1016\/j.biomaterials.2010.12.029","article-title":"Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization","volume":"32","author":"Xue","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2024.01.005_bib101","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s13346-013-0161-z","article-title":"Lipid nanoparticle delivery systems for siRNA-based therapeutics","volume":"4","author":"Wan","year":"2014","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ymthe.2024.01.005_bib102","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/mt.2013.124","article-title":"Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics","volume":"21","author":"Maier","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.01.005_bib103","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1038\/mtna.2014.61","article-title":"Shielding of lipid nanoparticles for siRNA delivery: impact on physicochemical properties, cytokine induction, and efficacy","volume":"3","author":"Kumar","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2024.01.005_bib104","doi-asserted-by":"crossref","first-page":"eabm1418","DOI":"10.1126\/sciadv.abm1418","article-title":"Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia","volume":"8","author":"Hu","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2024.01.005_bib105","first-page":"590","article-title":"Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy","volume":"9","author":"Li","year":"2022","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.ymthe.2024.01.005_bib106","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/pharmaceutics5030498","article-title":"Advances in lipid nanoparticles for siRNA delivery","volume":"5","author":"Tam","year":"2013","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2024.01.005_bib107","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nbt.2614","article-title":"Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling","volume":"31","author":"Sahay","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib108","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.bbrc.2014.01.107","article-title":"Cell-penetrating peptide-conjugated lipid nanoparticles for siRNA delivery","volume":"444","author":"Asai","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2024.01.005_bib109","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/EXP.20210008","article-title":"Membrane-destabilizing ionizable lipid empowered imaging-guided siRNA delivery and cancer treatment","volume":"1","author":"Guo","year":"2021","journal-title":"Exploration"},{"key":"10.1016\/j.ymthe.2024.01.005_bib110","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/j.ymthe.2021.05.004","article-title":"A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19","volume":"29","author":"Idris","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.01.005_bib111","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fphar.2014.00077","article-title":"Multifunctional polymeric micelles for delivery of drugs and siRNA","volume":"5","author":"Jhaveri","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib112","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1773-2247(12)50004-3","article-title":"Polymeric micelles for siRNA delivery","volume":"22","author":"Falamarzian","year":"2012","journal-title":"J.\u00a0Drug Deliv. Sci. Tec"},{"key":"10.1016\/j.ymthe.2024.01.005_bib113","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1021\/bm1005992","article-title":"Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18\u00a0F (ab\u2032) 2 for hepatocellular carcinoma","volume":"11","author":"Jin","year":"2010","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ymthe.2024.01.005_bib114","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/wnan.1332","article-title":"Applications of polymer micelles for imaging and drug delivery","volume":"7","author":"Movassaghian","year":"2015","journal-title":"Wires Nanomed Nanobi"},{"key":"10.1016\/j.ymthe.2024.01.005_bib115","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jconrel.2006.05.023","article-title":"PEG conjugated VEGF siRNA for anti-angiogenic gene therapy","volume":"116","author":"Kim","year":"2006","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.ymthe.2024.01.005_bib116","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1021\/ja044941d","article-title":"Lactosylated poly (ethylene glycol)-siRNA conjugate through acid-labile \u03b2-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells","volume":"127","author":"Oishi","year":"2005","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ymthe.2024.01.005_bib117","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/btpr.310","article-title":"Multifunctional siRNA delivery system: Polyelectrolyte complex micelles of six-arm PEG conjugate of siRNA and cell penetrating peptide with crosslinked fusogenic peptide","volume":"26","author":"Choi","year":"2010","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.ymthe.2024.01.005_bib118","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1021\/bc800249n","article-title":"LHRH Receptor-Mediated Delivery of siRNA Using Polyelectrolyte Complex Micelles Self-Assembled from siRNA-PEG-LHRH Conjugate and PEI","volume":"19","author":"Kim","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ymthe.2024.01.005_bib119","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jconrel.2008.03.008","article-title":"Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer","volume":"129","author":"Kim","year":"2008","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.ymthe.2024.01.005_bib120","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1021\/acs.nanolett.0c04468","article-title":"Core role of hydrophobic Core of polymeric nanomicelle in endosomal escape of siRNA","volume":"21","author":"Li","year":"2021","journal-title":"Nano Lett."},{"key":"10.1016\/j.ymthe.2024.01.005_bib121","doi-asserted-by":"crossref","first-page":"16701","DOI":"10.1021\/acsomega.0c01582","article-title":"Zeta Potential of Extracellular Vesicles: Toward Understanding the Attributes that Determine Colloidal Stability","volume":"5","author":"Midekessa","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.ymthe.2024.01.005_bib122","doi-asserted-by":"crossref","first-page":"10313","DOI":"10.1021\/acsnano.3c00668","article-title":"Delivery of engineered primary tumor-derived exosomes effectively suppressed the colorectal cancer chemoresistance and liver metastasis","volume":"17","author":"Huang","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.ymthe.2024.01.005_bib123","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12951-022-01472-z","article-title":"Recent advances in exosome-mediated nucleic acid delivery for cancer therapy","volume":"20","author":"Zhang","year":"2022","journal-title":"J.\u00a0Nanobiotechnol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib124","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","volume":"29","author":"Alvarez-Erviti","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2019.12.005","article-title":"Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis","volume":"318","author":"Zhao","year":"2020","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.ymthe.2024.01.005_bib126","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.2147\/IJN.S198353","article-title":"Lipid\u2013polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives","volume":"14","author":"Mukherjee","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ymthe.2024.01.005_bib127","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1021\/acsmaterialsau.3c00032","article-title":"Lipid-based nanoparticles for drug\/gene delivery: An overview of the production techniques and difficulties encountered in their industrial development","volume":"3","author":"Mehta","year":"2023","journal-title":"ACS Mater. Au"},{"key":"10.1016\/j.ymthe.2024.01.005_bib128","doi-asserted-by":"crossref","first-page":"18638","DOI":"10.1073\/pnas.1303958110","article-title":"Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug","volume":"110","author":"Xu","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.01.005_bib129","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41596-021-00665-4","article-title":"Synthesis of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic lesional macrophages","volume":"17","author":"Huang","year":"2022","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2024.01.005_bib130","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.addr.2013.09.019","article-title":"Nanomedicine therapeutic approaches to overcome cancer drug resistance","volume":"65","author":"Markman","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2024.01.005_bib131","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1021\/jp100271w","article-title":"Ability to adapt: different generations of PAMAM dendrimers show different behaviors in binding siRNA","volume":"114","author":"Pavan","year":"2010","journal-title":"J.\u00a0Phys. Chem. B"},{"key":"10.1016\/j.ymthe.2024.01.005_bib132","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1517\/17425247.2013.853661","article-title":"Poly(amidoamine) dendrimer complexes as a platform for gene delivery","volume":"10","author":"Shcharbin","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ymthe.2024.01.005_bib133","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijpharm.2016.09.083","article-title":"Dipeptide-functionalized polyamidoamine dendrimer-mediated apoptin gene delivery facilitates apoptosis of human primary glioma cells","volume":"515","author":"Bae","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ymthe.2024.01.005_bib134","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.actbio.2016.07.015","article-title":"PEGylated PAMAM dendrimers: Enhancing efficacy and mitigating toxicity for effective anticancer drug and gene delivery","volume":"43","author":"Luong","year":"2016","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ymthe.2024.01.005_bib135","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1016\/j.biomaterials.2011.04.047","article-title":"Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA","volume":"32","author":"Sakurai","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2024.01.005_bib136","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijpharm.2016.06.026","article-title":"Modulated cellular delivery of anti-VEGF siRNA (bevasiranib) by incorporating supramolecular assemblies of hydrophobically modified polyamidoamine dendrimer in stealth liposomes","volume":"510","author":"Golkar","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ymthe.2024.01.005_bib137","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/978-1-60761-609-2_19","article-title":"LHRH-targeted nanoparticles for cancer therapeutics","volume":"624","author":"Minko","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib138","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijpharm.2009.06.035","article-title":"Ethylendiamine core PAMAM dendrimers\/siRNA complexes as in\u00a0vitro silencing agents","volume":"380","author":"Perez","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ymthe.2024.01.005_bib139","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1021\/nn900201e","article-title":"Functional delivery of sirna in mice using dendriworms","volume":"3","author":"Agrawal","year":"2009","journal-title":"ACS Nano"},{"key":"10.1016\/j.ymthe.2024.01.005_bib140","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.2174\/1381612823666170314104619","article-title":"Surface engineered dendrimers in sirna delivery and gene silencing","volume":"23","author":"Tambe","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ymthe.2024.01.005_bib141","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jconrel.2021.10.028","article-title":"RGD engineered dendrimer nanotherapeutic as an emerging targeted approach in cancer therapy","volume":"340","author":"Sheikh","year":"2021","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.ymthe.2024.01.005_bib142","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1021\/acs.bioconjchem.9b00403","article-title":"Stereoselective pH responsive peptide dendrimers for siRNA transfection","volume":"30","author":"Heitz","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ymthe.2024.01.005_bib143","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/wnan.1233","article-title":"Bioengineered nanoparticles for siRNA delivery","volume":"5","author":"Kozielski","year":"2013","journal-title":"Wires Nanomed Nanobi"},{"key":"10.1016\/j.ymthe.2024.01.005_bib144","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/oli.2008.0112","article-title":"Induction of apoptosis in murine neuroblastoma by systemic delivery of transferrin-shielded siRNA polyplexes for downregulation of Ran","volume":"18","author":"Tietze","year":"2008","journal-title":"Oligonucleotides"},{"key":"10.1016\/j.ymthe.2024.01.005_bib145","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.addr.2006.09.008","article-title":"Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity","volume":"58","author":"Hunter","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2024.01.005_bib146","doi-asserted-by":"crossref","first-page":"32289","DOI":"10.1021\/acsami.0c06614","article-title":"ROS-activatable siRNA-engineered polyplex for nir-triggered synergistic cancer treatment","volume":"12","author":"Zhang","year":"2020","journal-title":"ACS Appl. Mater. Inter."},{"key":"10.1016\/j.ymthe.2024.01.005_bib147","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.biomaterials.2009.11.003","article-title":"The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine","volume":"31","author":"Alshamsan","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2024.01.005_bib148","doi-asserted-by":"crossref","first-page":"16028","DOI":"10.1073\/pnas.0407218101","article-title":"A polymer library approach to suicide gene therapy for cancer","volume":"101","author":"Anderson","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.01.005_bib149","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0168-3659(03)00076-2","article-title":"Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in\u00a0vivo distribution with high-molecular-weight polyethylenimine","volume":"89","author":"Kunath","year":"2003","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.ymthe.2024.01.005_bib150","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jconrel.2004.11.008","article-title":"Polyethylenimine with acid-labile linkages as a biodegradable gene carrier","volume":"103","author":"Kim","year":"2005","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.ymthe.2024.01.005_bib151","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s13346-020-00790-9","article-title":"PEI fluorination reduces toxicity and promotes liver-targeted siRNA delivery","volume":"11","author":"Xue","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ymthe.2024.01.005_bib152","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1016\/j.actbio.2010.06.016","article-title":"PEGylated PEI-based biodegradable polymers as non-viral gene vectors","volume":"6","author":"Huang","year":"2010","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ymthe.2024.01.005_bib153","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1163\/092050609X12459295750316","article-title":"PEG- and PDMAEG-graft-modified branched PEI as novel gene vector: Synthesis, characterization and gene transfection","volume":"21","author":"Wen","year":"2010","journal-title":"J.\u00a0Biomat Sci-polym E"},{"key":"10.1016\/j.ymthe.2024.01.005_bib154","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijpharm.2017.04.008","article-title":"Polymeric nanoparticles for siRNA delivery: Production and applications","volume":"525","author":"Cavallaro","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ymthe.2024.01.005_bib155","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2007.12.014","article-title":"Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice","volume":"127","author":"Kim","year":"2008","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.ymthe.2024.01.005_bib156","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2006.07.021","article-title":"Development and characterisation of chitosan nanoparticles for siRNA delivery","volume":"115","author":"Katas","year":"2006","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.ymthe.2024.01.005_bib157","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.progpolymsci.2006.06.001","article-title":"Chitin and chitosan: Properties and applications","volume":"31","author":"Rinaudo","year":"2006","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib158","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cossms.2013.01.002","article-title":"Cancer targeting strategies in nanomedicine: Design and application of chitosan nanoparticles","volume":"16","author":"Jee","year":"2012","journal-title":"Curr. Opin. Solid State Mater. Sci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib159","doi-asserted-by":"crossref","first-page":"405103","DOI":"10.1088\/0957-4484\/20\/40\/405103","article-title":"Functional gene silencing mediated by chitosan\/siRNA nanocomplexes","volume":"20","author":"Ji","year":"2009","journal-title":"Nanotechnology"},{"key":"10.1016\/j.ymthe.2024.01.005_bib160","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/03639040802526789","article-title":"Ultrafine chitosan nanoparticles as an efficient nucleic acid delivery system targeting neuronal cells","volume":"35","author":"Malhotra","year":"2009","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ymthe.2024.01.005_bib161","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s11095-009-0043-8","article-title":"New core-shell nanoparticules for the intravenous delivery of siRNA to experimental thyroid papillary carcinoma","volume":"27","author":"De Martimprey","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ymthe.2024.01.005_bib162","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3389\/fphar.2018.00307","article-title":"Targeting accessories to the crime: Nanoparticle nucleic acid delivery to the tumor microenvironment","volume":"9","author":"Harrison","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib163","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.biomaterials.2012.10.013","article-title":"Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases","volume":"34","author":"Malhotra","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2024.01.005_bib164","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3390\/pharmaceutics12060590","article-title":"Targeting activated hepatic stellate cells using collagen-binding chitosan nanoparticles for siRNA delivery to fibrotic livers","volume":"12","author":"Azzam","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2024.01.005_bib165","doi-asserted-by":"crossref","first-page":"e10764","DOI":"10.1371\/journal.pone.0010764","article-title":"Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma","volume":"5","author":"Susa","year":"2010","journal-title":"Plos One"},{"key":"10.1016\/j.ymthe.2024.01.005_bib166","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1021\/mp900015y","article-title":"The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic","volume":"6","author":"Davis","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2024.01.005_bib167","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ejps.2010.04.010","article-title":"PEGylation of biodegradable dextran nanogels for siRNA delivery","volume":"40","author":"Naeye","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib168","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1021\/bc100542r","article-title":"Acid-degradable cationic dextran particles for the delivery of siRNA therapeutics","volume":"22","author":"Cohen","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ymthe.2024.01.005_bib169","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.2217\/nnm-2016-0156","article-title":"Dextran-based therapeutic nanoparticles for hepatic drug delivery","volume":"11","author":"Foerster","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ymthe.2024.01.005_bib170","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2174\/138945011614151119130426","article-title":"Inulin derivatives obtained enhanced microwave synthesis for nucleic acid based drug delivery","volume":"16","author":"Sardo","year":"2015","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ymthe.2024.01.005_bib171","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1007\/s11095-015-1726-y","article-title":"Inulin-ethylenediamine coated SPIONs magnetoplexes: a promising tool for improving sirna delivery","volume":"32","author":"Licciardi","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ymthe.2024.01.005_bib172","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1021\/acs.biomac.6b00281","article-title":"Improvements in rational design strategies of inulin derivative polycation for siRNA delivery","volume":"17","author":"Sardo","year":"2016","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ymthe.2024.01.005_bib173","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejps.2015.03.021","article-title":"Development of a simple, biocompatible and cost-effective Inulin-Diethylenetriamine based siRNA delivery system","volume":"75","author":"Sardo","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib174","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ejpb.2014.09.008","article-title":"Inulin-based polymer coated SPIONs as potential drug delivery systems for targeted cancer therapy","volume":"88","author":"Scialabba","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ymthe.2024.01.005_bib175","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3390\/molecules26061713","article-title":"Development of new targeted inulin complex nanoaggregates for siRNA delivery in antitumor therapy","volume":"26","author":"Cavallaro","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ymthe.2024.01.005_bib176","doi-asserted-by":"crossref","first-page":"728","DOI":"10.2174\/0929867324666161205130416","article-title":"Current strategies in the modification of PLGA-based gene delivery system","volume":"24","author":"Ramezani","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ymthe.2024.01.005_bib177","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijpharm.2009.10.023","article-title":"Preparation and characterization of poly(DL-lactide-co-glycolide) nanoparticles for siRNA delivery","volume":"390","author":"Cun","year":"2010","journal-title":"Int. J. Pharm. X."},{"key":"10.1016\/j.ymthe.2024.01.005_bib178","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.biomaterials.2009.09.048","article-title":"The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance","volume":"31","author":"Patil","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2024.01.005_bib179","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1166\/jnn.2009.028","article-title":"Polymeric nanoparticles for sustained down-regulation of annexin A2 inhibit prostate tumor growth","volume":"9","author":"Braden","year":"2009","journal-title":"J.\u00a0Nanosci Nanotechno"},{"key":"10.1016\/j.ymthe.2024.01.005_bib180","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.3390\/ijms21103469","article-title":"CX3CR1-targeted PLGA nanoparticles reduce microglia activation and pain behavior in rats with spinal nerve ligation","volume":"21","author":"Noh","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib181","series-title":"The Development and in\u00a0Vitro Studies of PEI Modified Biodegradable PLGA Nanoparticles for Enhanced Non-viral siRNA Delivery","author":"Rathod","year":"2009"},{"key":"10.1016\/j.ymthe.2024.01.005_bib182","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijpharm.2008.09.039","article-title":"Polymeric nanoparticles for siRNA delivery and gene silencing","volume":"367","author":"Patil","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ymthe.2024.01.005_bib183","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12247-020-09496-4","article-title":"Efficiency of chitosan-coated PLGA nanocarriers for cellular delivery of siRNA and CRISPR\/Cas9 complex","volume":"17","author":"Srivastav","year":"2022","journal-title":"J.\u00a0Pharm. Innov."},{"key":"10.1016\/j.ymthe.2024.01.005_bib184","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/smll.201100761","article-title":"Five years of siRNA delivery: spotlight on gold nanoparticles","volume":"7","author":"Lytton-Jean","year":"2011","journal-title":"Small"},{"key":"10.1016\/j.ymthe.2024.01.005_bib185","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1246\/cl.2006.1046","article-title":"Smart PEGylated gold nanoparticles for the cytoplasmic delivery of siRNA to induce enhanced gene silencing","volume":"35","author":"Oishi","year":"2006","journal-title":"Chem. Lett."},{"key":"10.1016\/j.ymthe.2024.01.005_bib186","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1021\/nl802958f","article-title":"Polyvalent DNA nanoparticle conjugates stabilize nucleic acids","volume":"9","author":"Seferos","year":"2009","journal-title":"Nano Lett."},{"key":"10.1016\/j.ymthe.2024.01.005_bib187","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1021\/bc1002423","article-title":"Scavenger receptors mediate cellular uptake of polyvalent oligonucleotide-functionalized gold nanoparticles","volume":"21","author":"Patel","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ymthe.2024.01.005_bib188","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1021\/mp900172m","article-title":"Regulating immune response using polyvalent nucleic acid\u2212 gold nanoparticle conjugates","volume":"6","author":"Massich","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2024.01.005_bib189","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.biomaterials.2015.06.006","article-title":"Light-activated RNA interference in human embryonic stem cells","volume":"63","author":"Huang","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2024.01.005_bib190","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1021\/nl9009793","article-title":"Gold, poly (\u03b2-amino ester) nanoparticles for small interfering RNA delivery","volume":"9","author":"Lee","year":"2009","journal-title":"Nano Lett."},{"key":"10.1016\/j.ymthe.2024.01.005_bib191","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/smll.200901513","article-title":"Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery","volume":"6","author":"Song","year":"2010","journal-title":"Small"},{"key":"10.1016\/j.ymthe.2024.01.005_bib192","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/smll.201201141","article-title":"Dendronized gold nanoparticles for siRNA delivery","volume":"8","author":"Kim","year":"2012","journal-title":"Small"},{"key":"10.1016\/j.ymthe.2024.01.005_bib193","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/978-1-4939-9220-1_21","article-title":"Bioconjugated gold nanoparticles enhance siRNA delivery in prostate cancer cells","volume":"1974","author":"Rahme","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib194","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s11095-011-0554-y","article-title":"Cationic lipid-coated gold nanoparticles as efficient and non-cytotoxic intracellular siRNA delivery vehicles","volume":"29","author":"Kong","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ymthe.2024.01.005_bib195","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijpharm.2016.05.027","article-title":"Bioconjugated gold nanoparticles enhance cellular uptake: A proof of concept study for siRNA delivery in prostate cancer cells","volume":"509","author":"Guo","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ymthe.2024.01.005_bib196","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3390\/ijms22020831","article-title":"Layer by layer assembled chitosan-coated gold nanoparticles for enhanced siRNA delivery and silencing","volume":"22","author":"Shaabani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib197","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nm1486","article-title":"Imaging of siRNA delivery and silencing in tumors","volume":"13","author":"Medarova","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.01.005_bib198","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1002\/anie.200805998","article-title":"All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery","volume":"48","author":"Lee","year":"2009","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ymthe.2024.01.005_bib199","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1021\/bm3006903","article-title":"Cell-penetrating magnetic nanoparticles for highly efficient delivery and intracellular imaging of siRNA","volume":"13","author":"Qi","year":"2012","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ymthe.2024.01.005_bib200","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3390\/pharmaceutics11110615","article-title":"Efficient delivery of therapeutic siRNA by FeO magnetic nanoparticles into oral cancer cells","volume":"11","author":"Jin","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2024.01.005_bib201","doi-asserted-by":"crossref","first-page":"8156","DOI":"10.1158\/0008-5472.CAN-06-4762","article-title":"Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system","volume":"67","author":"Pan","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2024.01.005_bib202","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1021\/nn900918w","article-title":"Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs","volume":"3","author":"Xia","year":"2009","journal-title":"ACS Nano"},{"key":"10.1016\/j.ymthe.2024.01.005_bib203","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.biomaterials.2012.10.072","article-title":"A mesoporous silica nanoparticle\u2013PEI\u2013fusogenic peptide system for siRNA delivery in cancer therapy","volume":"34","author":"Li","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2024.01.005_bib204","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/adfm.201404629","article-title":"Cationic polymer modified mesoporous silica nanoparticles for targeted siRNA delivery to HER2 breast cancer","volume":"25","author":"Ngamcherdtrakul","year":"2015","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.ymthe.2024.01.005_bib205","doi-asserted-by":"crossref","first-page":"20531","DOI":"10.1038\/s41598-021-00085-0","article-title":"siRNA delivery using intelligent chitosan-capped mesoporous silica nanoparticles for overcoming multidrug resistance in malignant carcinoma cells","volume":"11","author":"Heidari","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2024.01.005_bib206","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/rb\/rbw010","article-title":"Calcium phosphate nanoparticles-based systems for siRNA delivery","volume":"3","author":"Xu","year":"2016","journal-title":"Regen. Biomater."},{"key":"10.1016\/j.ymthe.2024.01.005_bib207","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/adhm.201200088","article-title":"siRNA transfection with calcium phosphate nanoparticles stabilized with PEGylated chelators","volume":"2","author":"Giger","year":"2013","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.ymthe.2024.01.005_bib208","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.colsurfb.2017.06.028","article-title":"Synthesis and characterization of amino acid-functionalized calcium phosphate nanoparticles for siRNA delivery","volume":"158","author":"Bakan","year":"2017","journal-title":"Colloid Surf. B"},{"key":"10.1016\/j.ymthe.2024.01.005_bib209","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.2147\/IJN.S142739","article-title":"VEGF siRNA delivered by polycation liposome-encapsulated calcium phosphate nanoparticles for tumor angiogenesis inhibition in breast cancer","volume":"12","author":"Chen","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ymthe.2024.01.005_bib210","doi-asserted-by":"crossref","first-page":"111340","DOI":"10.1016\/j.colsurfb.2020.111340","article-title":"Silencing of survivin and cyclin B1 through siRNA-loaded arginine modified calcium phosphate nanoparticles for non-small-cell lung cancer therapy","volume":"196","author":"Kara","year":"2020","journal-title":"Colloid Surf. B"},{"key":"10.1016\/j.ymthe.2024.01.005_bib211","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.biomaterials.2013.10.032","article-title":"A review of ligand tethered surface engineered carbon nanotubes","volume":"35","author":"Mehra","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2024.01.005_bib212","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/978-1-0716-1298-9_12","article-title":"siRNA design and delivery based on carbon nanotubes","volume":"2282","author":"Li","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib213","series-title":"Gene Delivery","first-page":"103","article-title":"siRNA Delivery for Therapeutic Applications Using Nanoparticles","author":"Barua","year":"2022"},{"key":"10.1016\/j.ymthe.2024.01.005_bib214","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijpharm.2015.02.031","article-title":"Single-walled carbon nanotubes functionalized with aptamer and piperazine\u2013polyethylenimine derivative for targeted siRNA delivery into breast cancer cells","volume":"485","author":"Mohammadi","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ymthe.2024.01.005_bib215","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.18632\/aging.103905","article-title":"Multiwalled carbon nanotubes co-delivering sorafenib and epidermal growth factor receptor siRNA enhanced tumor-suppressing effect on liver cancer","volume":"13","author":"Wen","year":"2021","journal-title":"Aging-Us"},{"key":"10.1016\/j.ymthe.2024.01.005_bib216","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1021\/bc800278e","article-title":"siRNA conjugate delivery systems","volume":"20","author":"Jeong","year":"2009","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ymthe.2024.01.005_bib217","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/nat.2022.0038","article-title":"Cholesterol-conjugated siRNA silencing TNF for the treatment of liver macrophage-mediated acute inflammation in nonalcoholic fatty liver disease","volume":"33","author":"Craig","year":"2023","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2024.01.005_bib218","doi-asserted-by":"crossref","first-page":"100128","DOI":"10.1016\/j.medidd.2022.100128","article-title":"Antibody\u2013siRNA conjugates (ARC): Emerging siRNA drug formulation","volume":"15","author":"Cao","year":"2022","journal-title":"Med. Drug Discov."},{"key":"10.1016\/j.ymthe.2024.01.005_bib219","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1039\/D2SC01672A","article-title":"A photoresponsive antibody\u2013siRNA conjugate for activatable immunogene therapy of cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib220","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.matt.2022.04.032","article-title":"Transforming \u201ccold\u201d tumors into \u201chot\u201d ones via tumor-microenvironment-responsive siRNA micelleplexes for enhanced immunotherapy","volume":"5","author":"Yi","year":"2022","journal-title":"Matter"},{"key":"10.1016\/j.ymthe.2024.01.005_bib221","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1021\/acs.molpharmaceut.9b00633","article-title":"Cyclic cell-penetrating peptides as efficient intracellular drug delivery tools","volume":"16","author":"Park","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2024.01.005_bib222","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1039\/C2MB25467K","article-title":"Cell-penetrating peptides (CPPs) as a vector for the delivery of siRNAs into cells","volume":"9","author":"Nakase","year":"2013","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.ymthe.2024.01.005_bib223","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0005-2736(00)00216-9","article-title":"Deletion analogues of transportan","volume":"1467","author":"Soomets","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2024.01.005_bib224","series-title":"Open-label Study of Patisiran in Patients with hATTR Amyloidosis Post-Orthotopic Liver Transplant (2144)","author":"Coelho","year":"2021"},{"key":"10.1016\/j.ymthe.2024.01.005_bib225","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.omtn.2019.12.004","article-title":"Improved nucleic acid therapy with advanced nanoscale biotechnology","volume":"19","author":"Weng","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2024.01.005_bib226","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2024.01.005_bib227","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis","volume":"77","author":"Wright","year":"2021","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib228","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ekir.2021.12.001","article-title":"Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1","volume":"7","author":"Hulton","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.ymthe.2024.01.005_bib229","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.jaccas.2020.10.004","article-title":"Disease-modifying therapy for transthyretin amyloidosis: Where to start?","volume":"2","author":"Fine","year":"2020","journal-title":"JACC. Case Rep."},{"key":"10.1016\/j.ymthe.2024.01.005_bib230","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.tips.2020.08.004","article-title":"Paving the Road for RNA Therapeutics","volume":"41","author":"Dammes","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib231","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2021-150273","article-title":"Efficacy and safety of Fitusiran Prophylaxis, an siRNA therapeutic, in a multicenter phase 3 study (ATLAS-INH) in people with hemophilia A or B, with Inhibitors (PwHI)","volume":"138","author":"Young","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.01.005_bib232","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.kint.2021.08.015","article-title":"Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria","volume":"101","author":"Hoppe","year":"2022","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2024.01.005_bib233","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41581-021-00449-9","article-title":"A new era of treatment for primary hyperoxaluria type 1","volume":"17","author":"Erger","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib234","doi-asserted-by":"crossref","first-page":"114432","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: Updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib235","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2174\/1570159X15666170915142727","article-title":"Novel Therapeutics in Glaucoma Management","volume":"16","author":"Bucolo","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib236","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/13543784.2018.1457647","article-title":"Tivanisiran, a novel siRNA for the treatment of dry eye disease","volume":"27","author":"Moreno-Monta\u00f1\u00e9s","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ymthe.2024.01.005_bib237","first-page":"866","article-title":"Results of a phase 1b\/2 trial of intravitreal (IVT) sepofarsen (QR-110) antisense oligonucleotide in Leber congenital amaurosis 10 (LCA10) due to p.Cys998X mutation in the gene","volume":"61","author":"Russell","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib238","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1182\/blood-2021-146205","volume":"138","author":"van Zyl","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.01.005_bib239","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.drudis.2022.04.013","article-title":"Novel and investigational therapies for wet and dry age-related macular degeneration","volume":"27","author":"Sarkar","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymthe.2024.01.005_bib240","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.apsb.2022.01.007","article-title":"Multifunctional regulatory protein connective tissue growth factor (CTGF): A potential therapeutic target for diverse diseases","volume":"12","author":"Fu","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ymthe.2024.01.005_bib241","doi-asserted-by":"crossref","first-page":"114113","DOI":"10.1016\/j.addr.2022.114113","article-title":"RNAi-based therapeutics and tumor targeted delivery in cancer","volume":"182","author":"Kara","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2024.01.005_bib242","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3390\/cancers14061588","article-title":"Clinical applications of short non-coding RNA-based therapies in the era of precision medicine","volume":"14","author":"Smith","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ymthe.2024.01.005_bib243","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.3390\/ijms23052736","article-title":"Current advances in RNA therapeutics for human diseases","volume":"23","author":"Zogg","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib244","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3390\/pharmaceutics14020260","article-title":"Oligonucleotide therapeutics: From discovery and development to patentability","volume":"14","author":"Moumn\u00e9","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2024.01.005_bib245","series-title":"MicroRNA in Human Malignancies","first-page":"153","article-title":"Opportunities of miRNAs in cancer therapeutics","author":"Arenas","year":"2022"},{"key":"10.1016\/j.ymthe.2024.01.005_bib246","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1165\/rcmb.2021-0342TR","article-title":"Fighting the fiber: Targeting collagen in lung fibrosis","volume":"66","author":"Staab-Weijnitz","year":"2022","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib247","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/CM9.0000000000001994","article-title":"Advances in new antivirals for chronic hepatitis B","volume":"135","author":"Tang","year":"2022","journal-title":"Chin Med. J. (Engl)"},{"key":"10.1016\/j.ymthe.2024.01.005_bib248","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.3390\/ijms23052441","article-title":"A review of Alpha-1 antitrypsin binding partners for immune regulation and potential therapeutic application","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib249","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2024.01.005_bib250","first-page":"1489A","article-title":"First clinical experience with RNA interference-based triple combination therapy in chronic hepatitis B: JNJ-3989, JNJ-6379 and a Nucleos(t)ide analogue","volume":"70","author":"Yuen","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2024.01.005_bib251","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.01.005_bib252","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00733-2020","article-title":"Anti-HSP47 siRNA lipid nanoparticle ND-L02-s0201 reverses interstitial pulmonary fibrosis in preclinical rat models","volume":"7","author":"Liu","year":"2021","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.ymthe.2024.01.005_bib253","doi-asserted-by":"crossref","first-page":"A10357","DOI":"10.1161\/circ.144.suppl_1.10357","article-title":"ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia","volume":"144","author":"Clifton","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2024.01.005_bib254","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1097\/01.hjh.0000744440.87593.16","article-title":"Safety, pharmacodynamics, and blood pressure effects of ALN-AGT, an Rna interference therapeutic targeting angiotensinogen, in a randomized single ascending dose study of hypertensive adults","volume":"39","author":"Huang","year":"2021","journal-title":"J.\u00a0Hypertens."},{"key":"10.1016\/j.ymthe.2024.01.005_bib255","doi-asserted-by":"crossref","first-page":"A15751","DOI":"10.1161\/circ.142.suppl_3.15751","article-title":"Pharmacodynamic effect of ARO-ANG3, an investigational RNA interference targeting hepatic angiopoietin-like protein 3, in patients with hypercholesterolemia","volume":"142","author":"Watts","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2024.01.005_bib256","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/liv.14851","article-title":"HBV 2021: New therapeutic strategies against an old foe","volume":"41","author":"Roca Suarez","year":"2021","journal-title":"Liver Int."},{"key":"10.1016\/j.ymthe.2024.01.005_bib257","doi-asserted-by":"crossref","first-page":"109997","DOI":"10.1016\/j.biopha.2020.109997","article-title":"RNA-based pharmacotherapy for tumors: From bench to clinic and back","volume":"125","author":"Liang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ymthe.2024.01.005_bib258","doi-asserted-by":"crossref","first-page":"2130002","DOI":"10.1142\/S1793984421300028","article-title":"Nonviral vehicles for gene delivery","volume":"11","author":"Warga","year":"2021","journal-title":"Nano Life"},{"key":"10.1016\/j.ymthe.2024.01.005_bib259","doi-asserted-by":"crossref","first-page":"113842","DOI":"10.1016\/j.addr.2021.113842","article-title":"Highly branched poly (\u03b2-amino ester) s for gene delivery in hereditary skin diseases","volume":"176","author":"Zeng","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2024.01.005_bib260","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.tips.2021.05.001","article-title":"Iron metabolism: pathophysiology and pharmacology","volume":"42","author":"Roemhild","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib261","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/cancers14010020","article-title":"Autophagy and ncRNAs: Dangerous liaisons in the crosstalk between the tumor and its microenvironment","volume":"14","author":"Eng","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ymthe.2024.01.005_bib262","doi-asserted-by":"crossref","first-page":"102209","DOI":"10.1016\/j.coph.2022.102209","article-title":"Sustained inhibition of ENaC in CF: Potential RNA-based therapies for mutation-agnostic treatment Pradeep Kota","volume":"64","author":"Kota","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib263","doi-asserted-by":"crossref","first-page":"102098","DOI":"10.1016\/j.pupt.2021.102098","article-title":"Small-molecule drugs for cystic fibrosis: Where are we now?","volume":"72","author":"Laselva","year":"2022","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2024.01.005_bib264","first-page":"S742","article-title":"ALG-125755, a small interfering RNA (siRNA) against hepatitis B virus (HBV) effectively inhibits hepatitis B surface antigen (HBsAg) secretion in HBV cell models and the AAV-HBV mouse model","volume":"75","author":"Hong","year":"2021","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib265","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.thromres.2020.08.040","article-title":"Knockdown of liver-derived factor XII by GalNAc-siRNA ALN-F12 prevents thrombosis in mice without impacting hemostatic function","volume":"196","author":"Liu","year":"2020","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ymthe.2024.01.005_bib266","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/s41587-019-0351-4","article-title":"PCSK9-gene-silencing, cholesterol-lowering drug impresses","volume":"37","author":"Sheridan","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib267","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.apsb.2020.10.005","article-title":"Small interfering RNA for cancer treatment: overcoming hurdles in delivery","volume":"10","author":"Charbe","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ymthe.2024.01.005_bib268","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrg2936","article-title":"Gene silencing by microRNAs: contributions of translational repression and mRNA decay","volume":"12","author":"Huntzinger","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2024.01.005_bib269","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/IJN.S1253","article-title":"Tumor targeting using liposomal antineoplastic drugs","volume":"3","author":"Huwyler","year":"2008","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ymthe.2024.01.005_bib270","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.addr.2015.01.007","article-title":"Preclinical and clinical development of siRNA-based therapeutics","volume":"87","author":"Ozcan","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2024.01.005_bib271","first-page":"782041","article-title":"Recent developments in nanoparticle-based siRNA delivery for cancer therapy","volume":"2013","author":"Lee","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ymthe.2024.01.005_bib272","series-title":"Treatments and Vaccines","year":"2021"},{"key":"10.1016\/j.ymthe.2024.01.005_bib273","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","article-title":"Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date","volume":"33","author":"Bobo","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ymthe.2024.01.005_bib274","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/1567201817999200730211718","article-title":"Recent advances in treatment of lung cancer: Nanoparticle-based drug and siRNA delivery systems","volume":"18","author":"Gencer","year":"2021","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ymthe.2024.01.005_bib275","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1021\/cb600063p","article-title":"Gene silencing activity of siRNAs with a ribo-difluorotoluyl nucleotide","volume":"1","author":"Xia","year":"2006","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ymthe.2024.01.005_bib276","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/nar\/gkl033","article-title":"Improvements in siRNA properties mediated by 2\u2032-deoxy-2\u2032-fluoro-\u03b2-d-arabinonucleic acid (FANA)","volume":"34","author":"Dowler","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2024.01.005_bib277","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/nar\/gkg147","article-title":"Tolerance for mutations and chemical modifications in a siRNA","volume":"31","author":"Amarzguioui","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2024.01.005_bib278","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.biomaterials.2010.10.019","article-title":"The modification of siRNA with 3\u2032 cholesterol to increase nuclease protection and suppression of native mRNA by select siRNA polyplexes","volume":"32","author":"Ambardekar","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2024.01.005_bib279","doi-asserted-by":"crossref","first-page":"201","DOI":"10.7150\/thno.5743","article-title":"Optimized siRNA-PEG Conjugates for Extended Blood Circulation and Reduced Urine Excretion in Mice","volume":"3","author":"Iversen","year":"2013","journal-title":"Theranostics"},{"key":"10.1016\/j.ymthe.2024.01.005_bib280","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jconrel.2007.04.018","article-title":"Polymer brush-stabilized polyplex for a siRNA carrier with long circulatory half-life","volume":"122","author":"Sato","year":"2007","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.ymthe.2024.01.005_bib281","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/nat.2020.0848","article-title":"Effects of chemical modifications on siRNA strand selection in mammalian cells","volume":"30","author":"Varley","year":"2020","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2024.01.005_bib282","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1089\/oli.2009.0180","article-title":"siRNA and Innate Immunity","volume":"19","author":"Robbins","year":"2009","journal-title":"Oligonucleotides"},{"key":"10.1016\/j.ymthe.2024.01.005_bib283","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3390\/ijms13010516","article-title":"Biodegradable nanoparticles of mPEG-PLGA-PLL triblock copolymers as novel non-viral vectors for improving siRNA delivery and gene silencing","volume":"13","author":"Du","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.01.005_bib284","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.3390\/molecules25112692","article-title":"Lipid and polymer-based nanoparticle siRNA delivery systems for cancer therapy","volume":"25","author":"Mainini","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ymthe.2024.01.005_bib285","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1021\/bc8000722","article-title":"Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery","volume":"19","author":"Patil","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ymthe.2024.01.005_bib286","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2024.01.005_bib287","doi-asserted-by":"crossref","first-page":"10939","DOI":"10.1039\/D0NR00301H","article-title":"A photo-triggerable aptamer nanoswitch for spatiotemporal controllable siRNA delivery","volume":"12","author":"Zhao","year":"2020","journal-title":"Nanoscale"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624000054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624000054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:47:23Z","timestamp":1777618043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624000054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":287,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1525001624000054"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.01.005","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The landscape of nanoparticle-based siRNA delivery and therapeutic development","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}